Analysis of renal impairment in children with Wilsons disease
In SUSTAIN-6, wherein semaglutide (subcutaneous injection) was administered at 0.5 or 1 mg per week, MACE was also reduced by 26% in the semaglutide group compared with the placebo group (HR 0.74, 95% CI 0.580.95) as was stroke (HR 0.61, 95% CI 0.380.99) [17]
These changes are often related to fluid shifts or normal body adjustment to the medication
This is not clearly indicated in the product labels for GA, interferon , or dimethyl fumarate, although patients report stopping a few weeks to 3 months before trying to conceive
These rare side effects include an increased heart rate, low blood sugar, gallbladder issues, and pancreatitis